INTRODUCTION
============

One hallmark of HIV pathogenesis is a decline of CD4 T cell number that results from the death of both HIV-1 infected CD4 T cells, as well as uninfected cells. Both HIV expressed proteins, as well as immune activation, contribute to this T cell death \[[@R1]\]. Immune activation leads to an increase in T cell turnover from enhanced proliferation which in turn is associated with high rates of apoptosis \[[@R2],[@R3]\]. The magnitude of immune activation correlates with the level of HIV viremia \[[@R4]\]. Increased expression of immune activation markers (HLA-DR+, CD38+, CD45RO+, and CD95) also correlates with higher apoptosis rates of CD4 T cells \[[@R5]\]. Importantly, suppression of viral replication with HAART treatment reduces immune activation \[[@R6],[@R7]\], normalizes expression of activation markers, and decreases CD4 T cell apoptosis \[[@R8]-[@R10]\].

As a result of chronic immune activation, central memory and naïve CD4 T cells are constantly recruited into the effector pool \[[@R11],[@R12]\] resulting in dramatic changes in populations of naïve, effector and central memory CD4 T cells \[[@R13]\]. The mechanisms of how the ratio of these CD4 T cells is altered during HIV infection are not completely understood.

In particular, chronic HIV infection results in an increased number of CD4 T cells with a peculiar double positive CD45RO+/CD45RA+/CD25+CD4+ phenotype, and this subset is further increased following intermittent IL-2 therapy \[[@R14]\]. The origin of this subset was previously ascribed to be transition phase of naïve CD45RO-/CD45RA+CD4 T cells transitioning to a memory CD45RO+/CD45RA-CD4 T cell phenotype \[[@R15]\]. Furthermore, HAART with IL-2 therapy selectively increases the number of activated CD4 T cell expressing CD45RO+/CD25+ \[[@R16]\]. Here we describe a novel effect of HIV-1 gp120 signaling through CD4 resulting in altered CD45 isoform expression by CD4 T cells.

MATERIALS AND METHODOLOGY
=========================

Cell Culture and Reagents
-------------------------

This protocol was reviewed and approved by the Mayo institutional review board. CD4+ T cells were isolated from the blood of healthy volunteer blood donors by using RossetteSep CD4 enrichment cocktail (StemCell Technologies, Vancouver, British Columbia, Canada), producing 98% pure CD4+ T cells as determined by flow cytometry. CD4 T cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 2 mM L-glutamine, and antibiotics (penicillin 100 U/ml, streptomycin 100 μg/ml) at 0.5x10^6^ cells/ml. CD4+ T cells used in the various experiments were stimulated with PHA (1 μg/ml) for 24 hours, and then cells were washed twice with RPMI 1640 and maintained in media supplemented with 50 U/ml of IL-2 for 48-72 hours. CD4 T cells were incubated with HIV-1 X4 gp120IIIB (Immuno Diagnostics, Inc. Woburn, MA) or gp120 IIIB pretreated with soluble CD4 (1:2 ratio) (Immuno Diagnostics, Inc. Woburn, MA) at concentrations of 1 μg/ml/2x10^6^ cells for 24 hours at 37°C. AMD3100 (NIH AIDS Research and Reference program) was used at 2 μM for 30 minutes at 37°C. PP2 was purchased from CalBiochem (La Jolla, CA). Anti-CD4-PE, anti-CD25-FITC, anti-CD69-PE, anti-CD4PerCP, anti-CD62L-PE, anti-CD45RO-FITC, anti-CD45RA-PE-Cy-7, anti-HLA-DR-PE, AnnexinV-Cy-5, AnnexinV-APC, IgG1κ-PE-Cy7, IgG2a-FITC, IgG1κ-PE and propidium iodine were purchased from BD Biosciences (San Jose, CA).

Cell Death Analysis and Flow Cytometry
--------------------------------------

CD4 T cells were untreated or pre-incubated with specific inhibitors and stimulated with either BSA or with soluble gp120IIIB (10μg/ml) overnight. The following day, cell death was analyzed by staining with AnnexinV-Cy-5 and propidium iodine following the manufacturer's instructions from BD Biosciences (San Jose, CA). All experiments were performed at least three times.

T cell phenotyping studies were performed by using four-color Flow analysis on FACSCanto cytometer and using FACSDiva 6.0 software. Briefly, 2x10^6^ cells were resuspended in 200μl of PBS+0.5%BSA, stained with the indicated primary conjugated antibodies for 20 minutes (anti-CD45RO-FITC, anti-CD45RA-PE-Cy-7, anti-CD27 APC and anti-CD62L-PE), washed, fixed and then analyzed. In some cases, for analysis of cell death, cells were stained in binding buffer (140 mM NaCl, 10 mM HEPES/NaOH (pH 7.4), 2.5 mM CaCl2) as described above except that anti-CD62L-PE was substituted with AnnexinV-PE.

RESULTS
=======

Gp120 Decreases CD45RO+ Memory Phenotype in Activated But Not Resting CD4 T cells
---------------------------------------------------------------------------------

We and others have previously demonstrated that gp120 induces death of resting CD4 T cell in a CXCR4-p38 dependent manner \[[@R17]\]. However, the effect of gp120 on activated CD4 T cells is largely unknown. To examine the effect of gp120, resting (CD4+CD25-CD69-HLA-DR-) and activated (CD4+ CD25+CD69+HLA-DR+) primary human CD4 T cells were treated with gp120 IIIB (10μg/ml) for 24 hours and then CD4 T cells were analyzed for CD45R0 and CD45RA expression by flow cytometry. As shown in Fig. (**[1A](#F1){ref-type="fig"}**), gp120 treatment results in a 50% decrease in the subset of single positive CD45R0+/CD45RA- (31.85 ± 0.63% with BSA, 13.80 ± 3.73% with gp120, p=0.01) memory cells when activated but not resting CD4 T cells are treated with gp120 (34.25 ± 1.1% with BSA, 28.95 ± 1.96% with gp120, p=0.08). In parallel, there is a proportional increase in the subset of double positive CD45R0+/CD45RA+ mixed phenotype CD4+ T cells (Fig. **[1B](#F1){ref-type="fig"}**) as well as an increase in the proportion of Annexin-V positive CD4 T cells (Fig. **[1C](#F1){ref-type="fig"}**). While the increased apoptosis of resting cells following gp120 is due to CXCR4 signaling \[[@R17]\], the mechanisms by which gp120 causes death in activated cells are unknown.

The finding that gp120 treatment of activated cells increases the lymphoid homing marker, CD27 (13.8% of total CD4 T cells) preferentially in double positive CD45R0+/CD45RA+ cells suggests that these cells might be the specific cell type which dies following gp120 treatment of activated CD4 T cells (Fig. **[2A](#F2){ref-type="fig"}**, **[B](#F2){ref-type="fig"}**). We therefore measured absolute number and proportion of Annexin-V positivity of double positive CD45R0+/CD45RA+, single positive CD45R0-/CD45RA+ and CD45R0+/CD45RA- subsets by using four color flow cytometry analysis. First we observed that CD45RO+RA- proportion decreased (39.42 ± 3.44% with BSA, 27.31 ± 6.38% with gp120) while CD45RO+RA+ population increased (35.97 ± 2.70% with BSA, 49.42 ± 10.05% with gp120), suggesting that the former transitioned to the latter (Fig. **[3A](#F3){ref-type="fig"}**). Next we observed that only double positive CD45R0+/CD45RA+ CD4 T cell subset contain a significant proportion of Annexin positive cells (\~40%) in contrast to single positive CD45R0+/CD45RA- and CD45R0-/CD45RA+ subsets that do not (Fig. **[3B](#F3){ref-type="fig"}**). Therefore, gp120 signaling both activates cells towards a double positive phenotype and subsequently promotes their apoptotic death. Of interest, these Annexin positive CD45R0+/CD45 RA+ cells are also CD27+. Altogether these results indicate that gp120 treatment of activated CD4 T cells result in decrease memory CD45R0+/CD45RA- CD4 T cells due to accumulation of CD45R0+/CD45RA+ /CD27+ T cell subset that subsequently and selectively undergo apoptosis.

Gp120 Stimulated Accumulation of CD45RO+/CD45 RA+ CD4 T Cells Requires CD4 and Lck But Not CXCR4
------------------------------------------------------------------------------------------------

To investigate whether gp120 effect on CD45R0+/CD45RA+ CD4 T cell is due to ligation to CD4 or CXCR4, we used either soluble CD4 or the CXCR4 inhibitor, AMD3100. Independent experiments verified the activity of AMD3100 by blocking SDF-induced chemotaxis (data not shown). As shown in Fig. (**[4A](#F4){ref-type="fig"}**, **[B](#F4){ref-type="fig"}**), inhibition of CD4 ligation by sCD4 \[[@R17]\] blocks the increase in double positive CD45R0+/CD45RA+ memory cells. Consistent with this observation, inhibition of Lck activity with PP2 inhibitor also blocks increase in CD45R0+/CD45RA+ CD4 T cell subset. Conversely inhibition of gp120-CXCR4 interaction with AMD3100 \[[@R17]\] does not block completely gp120 mediated increase of CD45R0+/CD45RA+ CD4 T cells. Therefore, our results demonstrate that gp120 ligation to CD4 and subsequent activation of Lck results in accumulation of double positive CD45R0+/CD45RA+ memory CD4 T cells which subsequently and selectively undergo apoptosis in a CD4 dependent and CXCR4 independent manner.

DISCUSSION
==========

In the current report we have shown that gp120 treatment of activated CD4 T cells decreases the subset of single positive CD45R0+/CD45RA- CD4 T cells and increases the subset of double positive CD45R0+/CD45RA+ CD4 T cells which selectively undergo apoptosis. These results imply the gp120 may play a role in depletion of memory CD45R0+/ CD45RA- CD4 T during HIV.

Previously, the CD45R0+/CD45RA+ subset of CD4 T cells was characterized as a transition from naïve to effector phenotype during CD4 priming \[[@R15],[@R18]\] with increased expression of activation markers \[[@R19],[@R20]\]. The generation of this subset can occur in two ways: (i) the transition of recently activated of CD45RA+ T naïve cells to CD45R0+/ CD45RA+ phenotype \[[@R15],[@R21]\] and; (ii) re-expression of CD45RA isoform in the absence of Ag stimulation \[[@R15]\]. The fact that only few CD45R0+/CD45RA+ cells express markers of recently activated cells \[[@R19],[@R20]\] and upregulation of CD45RA+ (up to 10%) by CD45RO+/CD45RA- cells \[[@R15]\] suggest that gp120 rather upregulates CD45RA+ on single positive CD45RO+/CD45RA- memory CD4 T cells rather than promoting CD45RO expression on naïve CD4 T cells. Indeed, increase of double positive CD45RO+/CD45 RA+ CD4 T cells is followed by proportional decrease in CD45RO+/CD45RA- memory but not decrease in naïve CD45RO-/CD45RA+ CD4 T cells.

Others have shown that PBMC stimulated with staphylococcal enterotoxin A (SEA) in the presence of V3-derived gp120 peptides results in increase of CCR5+/CXCR4+/ CD45RO+ CD4 T cells followed by increased levels of apoptosis \[[@R22]\]. Our findings are in good agreement with this observation: first, both results demonstrate the gp120 mediated increase in transient state from naïve to activated CD4 T cells; second, both studies observe the increased apoptosis of activated CD4 T cells in the presence of gp120 or V3-derived peptide. However, our results highlight that gp120 priming of previously activated CD4 T cells reverses single positive CD45RO+/CD45RA- effector phenotype to double positive CD45RO+ /CD45RA+ transient phenotype.

The observation that double positive CD45R0+/CD45 RA+ preferentially undergo apoptosis presents one potential scenario of how inappropriately activated CD4 T cells die during HIV disease, and why IL-2 augments this process \[[@R16]\]. It is of further interest that gp120 treatment results in apoptosis of CD27+/CD45R0+/CD45RA+ cells. In fact, CD27 expression is rapidly upregulated following TCR stimulation \[[@R23]\] and CD27 signaling is essential for survival of Ag-primed CD4 T cells \[[@R24]\]. Therefore, either the lack of antigen specific signaling or the lack of CD27 signaling may explain the increased apoptosis of double positive CD45R0+/CD45RA+ following gp120 treatment. Finally, the observation that CD4 ligation by gp120 and subsequent activation of Lck is required for generation of double positive CD45R0+/CD45RA+ CD4 T cells is of relevance and suggests that inhibitors of CD4-gp120 interactions may reverse the expansion of double positive CD45R0+/CD45RA+ population and subsequent increased apoptosis during HIV infection.
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![**Gp120 decreases CD45RO+/CD45RA- memory phenotype in activated but not resting primary human CD4 T cells.** (**A** and **B**) CD4+ T cells (98% pure) were stimulated with PHA for 24 hours or left rested, and treated with either p120 (IIIB) (1µg/ml) or BSA control (1µg/ml) and analyzed for CD45RO and CD45RA (gated on CD4 population) by flow cytometry. (**C**) Resting and activated primary human CD4 T cells were treated with gp120 (IIIB) as above and analyzed for Annexin-V positive cells. Data is representative of three independent experiments.](TOVJ-3-21_F1){#F1}

![**Gp120 increases subset of CD27+/CD45RO+/CD4+ T cells.** (**A**) Activated primary human CD4 T cells (98% pure) were treated with gp120 IIIIB and the expression of CD27 and CD45RA were analyzed by flow cytometry. (**B**) Pooled data from three independent experiments. P values were determined by Student's paired t test.](TOVJ-3-21_F2){#F2}

![**Gp120 increases subset of double positive CD45RA+/CD45RO+ CD4 T cells that undergo apoptosis.** (**A**) Activated primary human CD4 T cells were treated with gp120 IIIIB and CD45RA+/CD45RO-, CD45RA-/CD45RO+ and double positive CD45RA+/CD45RO+ cells were quantified by flow cytometry. (**B**) Same as Fig. (**[3A](#F3){ref-type="fig"}**) except that CD27 expression and Annexin-V positivity were measured by four color flow cytometry. The data is representative of three independent experiments.](TOVJ-3-21_F3){#F3}

![**CD4 and Lck are required for gp120 mediated increase of double positive CD45RA+/CD45RO+ CD4 T cells.** (**A**) Activated primary human CD4 T cells were left untreated or were pre-treated with either Lck inhibitor, PP2 (5µM) or CXCR4 inhibitor, AMD3100 (2µM) or sCD4 (2µg/ml) followed by gp120. Then number of single positive CD45RA+/CD45RO-, CD45RA-/CD45RO+ and double positive CD45RA+/CD45RO+ cells were analyzed by flow cytometry. (**B**) The data represents three independent experiments as described above. P values were determined by Student's paired t test. \*=P\<0.05 compared to gp120 alone.](TOVJ-3-21_F4){#F4}
